N/A N=30 Diagnostic

Imaging Brain Tumors With FACBC and Methionine

Brain Cancer · CNS Cancer

Bottom Line

View on ClinicalTrials.gov: NCT00597246 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2020

Primary outcome: Primary: Maximum Standardized Uptake Value of 3-[18F]-FACBC — 4.5 SUVmax

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: FACBC, Methionine (Drug); PET Scan (Other)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Memorial Sloan Kettering Cancer Center
Primary completion: Nov 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Maximum Standardized Uptake Value of 3-[18F]-FACBC	4.5	—
SECONDARY Rate of 18F-Fluciclovine Transport (k1) Into Tumors	0.14	—

Summary

This research protocol makes pictures of brain tumors. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactivity to "see" cancer cells. We are using a new kind of PET scan. The new PET scan is called [18F]-FACBC PET. We will compare this to the standard PET scan. The standard PET scan is called [11C]-methionine PET. We expect these pictures will give us information about your tumor. We also hope to collect information about the amount of radioactivity exposure. We will measure radioactivity exposure to your tumor, brain and other organs. The research study results will be used to support the submission of an investigational new drug (IND) application to the Food and Drug Administration (FDA).

Eligibility Criteria

Inclusion Criteria

Registered patient at MSKCC.
Child-bearing age females must be non-pregnant, non-lactating, and must be using adequate contraception or surgically sterile.
Karnofsky score of 60 or greater.
Children that can sit still for 60-90 minutes, without sedation, will be included in this protocol.

Exclusion Criteria

Patient cannot tolerate lying still for 90 minute sessions in the PET tomograph.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00597246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.